LISCure Biosciences Inc.
PrivateLast Round
Private Equity
Jan 10, 2025
Est. Valuation
$80.6M
Total Funding Raised
$43.54M
Company Overview
LISCure Biosciences Inc. is a clinical-stage biotechnology company that develops bacteria-mediated cancer immunotherapy and oral microbiome therapeutics for oncology, liver diseases, neuroscience, and immunology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LISCure Biosciences Inc. Comparables
Compare LISCure Biosciences Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Exeliom Biosciences | 80% | |
| EnteroBiotix | 78% | |
| MRM Health | 77% |
LISCure Biosciences Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Jan 10, 2025 | ||||
| Strategic | Aug 1, 2021 | ||||
| Series B | Feb 25, 2021 | ||||
| Strategic | Dec 11, 2020 | ||||
| Strategic | Oct 28, 2020 | ||||
Strategic | Oct 21, 2020 |
Key People
Founding team and executive leadership
LISCure Biosciences Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IGIS Asset Management | Private Equity |
| KB Securities | Seed |
| Dt& Investment | Private Equity |
| Shinhan Securities | Seed |
| Yuanta Investment | Private Equity |
| InterValue Partners | Private Equity |
| NHN Investment | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 10, 2025
$14M round with participation from Dt& Investment and IBK Securities.
- Aug 1, 2021
Mayo Clinic participated in the strategic round.
LISCure Biosciences Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about LISCure Biosciences Inc.'s valuation, stock price, and market status.
Is LISCure Biosciences Inc. a public or private company?
LISCure Biosciences Inc. is a private company.
What is the current stock price of LISCure Biosciences Inc.?
LISCure Biosciences Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is LISCure Biosciences Inc. worth (valuation)?
LISCure Biosciences Inc.'s valuation is estimated at $80.6M based on funding round data.
Can I buy LISCure Biosciences Inc. stock?
LISCure Biosciences Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was LISCure Biosciences Inc.'s last funding round?
LISCure Biosciences Inc.'s most recent funding round was Growth Equity on January 10, 2025.
Who are the main investors in LISCure Biosciences Inc.?
Key investors in LISCure Biosciences Inc. include KB Securities, InterValue Partners, NHN Investment, IBK Securities, Yukyung PSG Asset Management.
Will LISCure Biosciences Inc. IPO soon?
No public IPO plans have been announced for LISCure Biosciences Inc..
How can I track LISCure Biosciences Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor LISCure Biosciences Inc.'s secondary market activity and sign up for updates.